FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1659-1672 October 20, 2005 Number 16 Next

Martine J. Piccart-Gebhart, M.D., Ph.D., Marion Procter, M.Sci., Brian Leyland-Jones, M.D., Ph.D., Aron Goldhirsch, M.D., Michael Untch, M.D., Ian Smith, M.D., Luca Gianni, M.D., Jose Baselga, M.D., Richard Bell, M.D., Christian Jackisch, M.D., David Cameron, M.D., Mitch Dowsett, Ph.D., Carlos H. Barrios, M.D., Günther Steger, M.D., Chiun-Shen Huang, M.D., Ph.D., M.P.H., Michael Andersson, M.D., Dr.Med.Sci., Moshe Inbar, M.D., Mikhail Lichinitser, M.D., István Láng, M.D., Ulrike Nitz, M.D., Hiroji Iwata, M.D., Christoph Thomssen, M.D., Caroline Lohrisch, M.D., Thomas M. Suter, M.D., Josef Rüschoff, M.D., Tamás Süt, M.D., Ph.D., Victoria Greatorex, M.Sc., Carol Ward, M.Sc., Carolyn Straehle, Ph.D., Eleanor McFadden, M.A., M. Stella Dolci, Richard D. Gelber, Ph.D., for the Herceptin Adjuvant (HERA) Trial Study Team

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Burstein, H. J. Editorial by Hortobagyi, G. N. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of chemotherapy.

Methods This international, multicenter, randomized trial compared one or two years of trastuzumab given every three weeks with observation in patients with HER2-positive and either node-negative or node-positive breast cancer who had completed locoregional therapy and at least four cycles of neoadjuvant or adjuvant chemotherapy.

Results Data were available for 1694 women randomly assigned to two years of treatment with trastuzumab, 1694 women assigned to one year of trastuzumab, and 1693 women assigned to observation. We report here the results only of treatment with trastuzumab for one year or observation. At the first planned interim analysis (median follow-up of one year), 347 events (recurrence of breast cancer, contralateral breast cancer, second nonbreast malignant disease, or death) were observed: 127 events in the trastuzumab group and 220 in the observation group. The unadjusted hazard ratio for an event in the trastuzumab group, as compared with the observation group, was 0.54 (95 percent confidence interval, 0.43 to 0.67; P<0.0001 by the log-rank test, crossing the interim analysis boundary), representing an absolute benefit in terms of disease-free survival at two years of 8.4 percentage points. Overall survival in the two groups was not significantly different (29 deaths with trastuzumab vs. 37 with observation). Severe cardiotoxicity developed in 0.5 percent of the women who were treated with trastuzumab.

Conclusions One year of treatment with trastuzumab after adjuvant chemotherapy significantly improves disease-free survival among women with HER2-positive breast cancer. (ClinicalTrials.gov number, NCT00045032 [ClinicalTrials.gov] .)

Source Information

Address reprint requests to Dr. Piccart-Gebhart at the Medicine Department, Jules Bordet Institute, Blvd. de Waterloo 125, 1000 Brussels, Belgium, or at martine.piccart{at}bordet.be. The authors' affiliations are listed in the Appendix.

Full Text of this Article

Related Letters:

Trastuzumab in Breast Cancer
Gilbert S. G., Banna G. L., Santoro A., Gounaris I. G., Katsumata M., Drebin J. A., Greene M. I., Mastrianni D. M., Mano M., Cameron D., Gelber R. D., the HERA Trial Study Team , Bryant J., Romond E., Perez E. A., Hortobagyi G. N., Barron H.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:640-644, Feb 9, 2006. Correspondence

This article has been cited by other articles:

• Fojo, T., Grady, C. (2009). How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI J Natl Cancer Inst 0: djp177v1-5 [Abstract] [Full Text]  
• Green, M. D., Francis, P. A., Gebski, V., Harvey, V., Karapetis, C., Chan, A., Snyder, R., Fong, A., Basser, R., Forbes, J. F., on behalf of the Australian New Zealand Breast Can, (2009). Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer. Ann Oncol 0: mdp202v1-mdp202 [Abstract] [Full Text]  
• Rhodes, D. R., Ateeq, B., Cao, Q., Tomlins, S. A., Mehra, R., Laxman, B., Kalyana-Sundaram, S., Lonigro, R. J., Helgeson, B. E., Bhojani, M. S., Rehemtulla, A., Kleer, C. G., Hayes, D. F., Lucas, P. C., Varambally, S., Chinnaiyan, A. M. (2009). AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist. Proc. Natl. Acad. Sci. USA 106: 10284-10289 [Abstract] [Full Text]  
• Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., Viale, G., Gelber, R. D., Piccart-Gebhart, M., Leyland-Jones, B. (2009). Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. JCO 27: 2962-2969 [Abstract] [Full Text]  
• Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J., Panel members, (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 0: mdp322v1-mdp322 [Abstract] [Full Text]  
• Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., Marks, L., Davidson, N., Martino, S., Kaufman, P., Kutteh, L., Dakhil, S. R., Perez, E. A. (2009). Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831. JCO 27: 2638-2644 [Abstract] [Full Text]  
• Onitilo, A. A., Engel, J. M., Greenlee, R. T., Mukesh, B. N. (2009). Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res 7: 4-13 [Abstract] [Full Text]  
• Zustin, J, Boddin, K, Tsourlakis, M C, Burandt, E, Mirlacher, M, Jaenicke, F, Izbicki, J, Ruether, W, Rueger, J M, Bokemeyer, C, Simon, R, Sauter, G (2009). HER-2/neu analysis in breast cancer bone metastases. J. Clin. Pathol. 62: 542-546 [Abstract] [Full Text]  
• Ejlertsen, B., Jensen, M.-B., Rank, F., Rasmussen, B. B., Christiansen, P., Kroman, N., Kvistgaard, M. E., Overgaard, M., Toftdahl, D. B., Mouridsen, H. T., on behalf of the Danish Breast Cancer Cooperative, (2009). Population-Based Study of Peritumoral Lymphovascular Invasion and Outcome Among Patients With Operable Breast Cancer. JNCI J Natl Cancer Inst 101: 729-735 [Abstract] [Full Text]  
• Quaye, L., Dafou, D., Ramus, S. J., Song, H., Maharaj, A. G., Notaridou, M., Hogdall, E., Kjaer, S. K., Christensen, L., Hogdall, C., Easton, D. F., Jacobs, I., Menon, U., Pharoah, P. D.P., Gayther, S. A. (2009). Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 18: 1869-1878 [Abstract] [Full Text]  
• Xenidis, N., Ignatiadis, M., Apostolaki, S., Perraki, M., Kalbakis, K., Agelaki, S., Stathopoulos, E. N., Chlouverakis, G., Lianidou, E., Kakolyris, S., Georgoulias, V., Mavroudis, D. (2009). Cytokeratin-19 mRNA-Positive Circulating Tumor Cells After Adjuvant Chemotherapy in Patients With Early Breast Cancer. JCO 27: 2177-2184 [Abstract] [Full Text]  
• BROOM, R. J., TANG, P. A., SIMMONS, C., BORDELEAU, L., MULLIGAN, A. M., O'MALLEY, F. P., MILLER, N., ANDRULIS, I. L., BRENNER, D. M., CLEMONS, M. J. (2009). Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer. Anticancer Res 29: 1557-1562 [Abstract] [Full Text]  
• Kataja, V., Castiglione, M., On behalf of the ESMO Guidelines Working Group, (2009). Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv10-iv14 [Full Text]  
• Benavides, L. C., Gates, J. D., Carmichael, M. G., Patel, R., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Craig, D., Stojadinovic, A., Ponniah, S., Peoples, G. E. (2009). The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 15: 2895-2904 [Abstract] [Full Text]  
• Sparano, J. A., Moulder, S., Kazi, A., Coppola, D., Negassa, A., Vahdat, L., Li, T., Pellegrino, C., Fineberg, S., Munster, P., Malafa, M., Lee, D., Hoschander, S., Hopkins, U., Hershman, D., Wright, J. J., Kleer, C., Merajver, S., Sebti, S. M. (2009). Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. Clin. Cancer Res. 15: 2942-2948 [Abstract] [Full Text]  
• Gong, Y., Sweet, W., Duh, Y.-J., Greenfield, L., Fang, Y., Zhao, J., Tarco, E., Symmans, W. F., Isola, J., Sneige, N. (2009). Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations. Am J Clin Pathol 131: 490-497 [Abstract] [Full Text]  
• Lennon, S., Barton, C., Banken, L., Gianni, L., Marty, M., Baselga, J., Leyland-Jones, B. (2009). Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer. JCO 27: 1685-1693 [Abstract] [Full Text]  
• Dolle, J. M., Daling, J. R., White, E., Brinton, L. A., Doody, D. R., Porter, P. L., Malone, K. E. (2009). Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. Cancer Epidemiol. Biomarkers Prev. 18: 1157-1166 [Abstract] [Full Text]  
• Spitale, A., Mazzola, P., Soldini, D., Mazzucchelli, L., Bordoni, A. (2009). Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20: 628-635 [Abstract] [Full Text]  
• Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
• Houshmandi, S. S., Emnett, R. J., Giovannini, M., Gutmann, D. H. (2009). The Neurofibromatosis 2 Protein, Merlin, Regulates Glial Cell Growth in an ErbB2- and Src-Dependent Manner. Mol. Cell. Biol. 29: 1472-1486 [Abstract] [Full Text]  
• Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E., Piccart, M. (2009). HER-2 as a Target for Breast Cancer Therapy. Clin. Cancer Res. 15: 1848-1852 [Full Text]  
• Sauter, G., Lee, J., Bartlett, J. M.S., Slamon, D. J., Press, M. F. (2009). Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations. JCO 27: 1323-1333 [Abstract] [Full Text]  
• Stokoe, C. (2009). Adapting Practice in the Face of New Data. J Oncol Pract 5: 83-85 [Full Text]  
• Iverson, A. A., Gillett, C., Cane, P., Santini, C. D., Vess, T. M., Kam-Morgan, L., Wang, A., Eisenberg, M., Rowland, C. M., Hessling, J. J., Broder, S. E., Sninsky, J. J., Tutt, A., Anderson, S., Chang, S.-Y. P. (2009). A Single-Tube Quantitative Assay for mRNA Levels of Hormonal and Growth Factor Receptors in Breast Cancer Specimens. J. Mol. Diagn. 11: 117-130 [Abstract] [Full Text]  
• Anton, A., Ruiz, A., Segui, M. A., Calvo, L., Munoz, M., Lao, J., Sancho, F., Fernandez, L. (2009). Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 20: 454-459 [Abstract] [Full Text]  
• Choi, Y. H., Ahn, J. H., Kim, S.-B., Jung, K.-H., Gong, G.-Y., Kim, M.-J., Son, B.-H., Ahn, S.-H., Kim, W. K. (2009). Tissue microarray-based study of patients with lymph node-negative breast cancer shows that HER2/neu overexpression is an important predictive marker of poor prognosis. Ann Oncol 0: mdp003v1-mdp003 [Abstract] [Full Text]  
• Dawood, S., Broglio, K., Kau, S.-W., Green, M. C., Giordano, S. H., Meric-Bernstam, F., Buchholz, T. A., Albarracin, C., Yang, W. T., Hennessy, B. T.J., Hortobagyi, G. N., Gonzalez-Angulo, A. M. (2009). Triple Receptor-Negative Breast Cancer: The Effect of Race on Response to Primary Systemic Treatment and Survival Outcomes. JCO 27: 220-226 [Abstract] [Full Text]  
• Bartlett, J. M.S., Ibrahim, M., Jasani, B., Morgan, J. M., Ellis, I., Kay, E., Connolly, Y., Campbell, F., O'Grady, A., Barnett, S., Miller, K. (2009). External Quality Assurance of HER2 FISH and ISH Testing: Three Years of the UK National External Quality Assurance Scheme. Am J Clin Pathol 131: 106-111 [Abstract] [Full Text]  
• Sinclair, S., Zimmer, A. S., Swain, S. M. (2009). HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer. Am Soc Clin Oncol Ed Book 2009: 3-10 [Abstract] [Full Text]  
• Cortes, J., Di Cosimo, S., Climent, M. A., Cortes-Funes, H., Lluch, A., Gascon, P., Mayordomo, J. I., Gil, M., Benavides, M., Cirera, L., Ojeda, B., Rodriguez, C. A., Trigo, J. M., Vazquez, J., Regueiro, P., Dorado, J. F., Baselga, J., on behalf of the Spanish Breast Cancer Cooperative, (2009). Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin. Cancer Res. 15: 307-314 [Abstract] [Full Text]  
• Morris, P. G., McArthur, H. L., Dang, C. T., Hudis, C. A. (2009). Selection of Appropriate Patients for Anthracycline Therapy. Am Soc Clin Oncol Ed Book 2009: 11-18 [Abstract] [Full Text]  
• Martin, M., Esteva, F. J., Alba, E., Khandheria, B., Perez-Isla, L., Garcia-Saenz, J. A., Marquez, A., Sengupta, P., Zamorano, J. (2009). Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. The Oncologist 14: 1-11 [Abstract] [Full Text]  
• Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., Gelmon, K. (2008). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. JCO 26: 5697-5704 [Abstract] [Full Text]  
• Ziogas, D., Ignatiadou, E., Roukos, D., Lykoudis, E. (2008). HER2 and Trastuzumab: Impact of a New Standard Agent on Local Control and Surgery for Breast Cancer. Ann. Surg. Oncol. 15: 3614-3615 [Full Text]  
• Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brunner, N., Chan, D. W., Babaian, R., Bast, R. C. Jr., Dowell, B., Esteva, F. J., Haglund, C., Harbeck, N., Hayes, D. F., Holten-Andersen, M., Klee, G. G., Lamerz, R., Looijenga, L. H., Molina, R., Nielsen, H. J., Rittenhouse, H., Semjonow, A., Shih, I.-M., Sibley, P., Soletormos, G., Stephan, C., Sokoll, L., Hoffman, B. R., Diamandis, E. P. (2008). National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers. Clin. Chem. 54: e11-e79 [Abstract] [Full Text]  
• Peintinger, F., Buzdar, A. U., Kuerer, H. M., Mejia, J. A., Hatzis, C., Gonzalez-Angulo, A. M., Pusztai, L., Esteva, F. J., Dawood, S. S., Green, M. C., Hortobagyi, G. N., Symmans, W. F. (2008). Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab. Ann Oncol 19: 2020-2025 [Abstract] [Full Text]  
• Dickler, M. N., Rugo, H. S., Eberle, C. A., Brogi, E., Caravelli, J. F., Panageas, K. S., Boyd, J., Yeh, B., Lake, D. E., Dang, C. T., Gilewski, T. A., Bromberg, J. F., Seidman, A. D., D'Andrea, G. M., Moasser, M. M., Melisko, M., Park, J. W., Dancey, J., Norton, L., Hudis, C. A. (2008). A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer. Clin. Cancer Res. 14: 7878-7883 [Abstract] [Full Text]  
• Lenihan, D. J., Esteva, F. J. (2008). Multidisciplinary Strategy for Managing Cardiovascular Risks When Treating Patients with Early Breast Cancer. The Oncologist 13: 1224-1234 [Abstract] [Full Text]  
• Vigna, E., Pacchiana, G., Mazzone, M., Chiriaco, C., Fontani, L., Basilico, C., Pennacchietti, S., Comoglio, P. M. (2008). "Active" Cancer Immunotherapy by Anti-Met Antibody Gene Transfer. Cancer Res. 68: 9176-9183 [Abstract] [Full Text]  
• Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blattler, W. A., Lambert, J. M., Chari, R. V.J., Lutz, R. J., Wong, W. L. T., Jacobson, F. S., Koeppen, H., Schwall, R. H., Kenkare-Mitra, S. R., Spencer, S. D., Sliwkowski, M. X. (2008). Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Res. 68: 9280-9290 [Abstract] [Full Text]  
• Carbone, A., Botti, G., Gloghini, A., Simone, G., Truini, M., Curcio, M. P., Gasparini, P., Mangia, A., Perin, T., Salvi, S., Testi, A., Verderio, P. (2008). Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists. J. Mol. Diagn. 10: 527-536 [Abstract] [Full Text]  
• Chen, F. L., Xia, W., Spector, N. L. (2008). Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors. Clin. Cancer Res. 14: 6730-6734 [Abstract] [Full Text]  
• Berruti, A., Brizzi, M. P., Generali, D., Ardine, M., Dogliotti, L., Bruzzi, P., Bottini, A. (2008). Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions. The Oncologist 13: 1137-1148 [Abstract] [Full Text]  
• Stagg, J., Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita, H., Johnstone, R. W., Smyth, M. J. (2008). Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc. Natl. Acad. Sci. USA 105: 16254-16259 [Abstract] [Full Text]  
• Dawood, S., Broglio, K., Gonzalez-Angulo, A. M., Buzdar, A. U., Hortobagyi, G. N., Giordano, S. H. (2008). Trends in Survival Over the Past Two Decades Among White and Black Patients With Newly Diagnosed Stage IV Breast Cancer. JCO 26: 4891-4898 [Abstract] [Full Text]  
• Vanden Bempt, I., Van Loo, P., Drijkoningen, M., Neven, P., Smeets, A., Christiaens, M.-R., Paridaens, R., De Wolf-Peeters, C. (2008). Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing. JCO 26: 4869-4874 [Abstract] [Full Text]  
• Qin, J., Jones, R. C., Ramakrishnan, R. (2008). Studying copy number variations using a nanofluidic platform. Nucleic Acids Res 36: e116-e116 [Abstract] [Full Text]  
• Menard, S., Balsari, A., Tagliabue, E., Camerini, T., Casalini, P., Bufalino, R., Castiglioni, F., Carcangiu, M. L., Gloghini, A., Scalone, S., Querzoli, P., Lunardi, M., Molino, A., Mandara, M., Mottolese, M., Marandino, F., Venturini, M., Bighin, C., Cancello, G., Montagna, E., Perrone, F., De Matteis, A., Sapino, A., Donadio, M., Battelli, N., Santinelli, A., Pavesi, L., Lanza, A., Zito, F. A., Labriola, A., Aiello, R. A., Caruso, M., Zanconati, F., Mustacchi, G., Barbareschi, M., Frisinghelli, M., Russo, R., Carrillo, G., On the behalf of the OMERO group, (2008). Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. Ann Oncol 19: 1706-1712 [Abstract] [Full Text]  
• Arteaga, C. L., O'Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., Davidson, N. E. (2008). A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clin. Cancer Res. 14: 6277-6283 [Abstract] [Full Text]  
• Srinivasan, S., Parsa, V., Liu, C. Y, Fontana, J. A (2008). Trastuzumab-Induced Hepatotoxicity. The Annals of Pharmacotherapy 42: 1497-1501 [Abstract] [Full Text]  
• Schmidt, M., Hasenclever, D., Schaeffer, M., Boehm, D., Cotarelo, C., Steiner, E., Lebrecht, A., Siggelkow, W., Weikel, W., Schiffer-Petry, I., Gebhard, S., Pilch, H., Gehrmann, M., Lehr, H.-A., Koelbl, H., Hengstler, J. G., Schuler, M. (2008). Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer. Clin. Cancer Res. 14: 5849-5855 [Abstract] [Full Text]  
• Roukos, D. H., Lykoudis, E., Liakakos, T. (2008). Genomics and Challenges Toward Personalized Breast Cancer Local Control. JCO 26: 4360-4361 [Full Text]  
• Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., Sledge, G. W. Jr, Perez, E. A., Shulman, L. N., Martino, S., Sparano, J. A. (2008). Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. JCO 26: 4063-4071 [Abstract] [Full Text]  
• King, J., Waxman, J., Stauss, H. (2008). Advances in tumour immunotherapy. QJM 101: 675-683 [Abstract] [Full Text]  
• Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., Suter, T. (2008). Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 19: 1530-1539 [Abstract] [Full Text]  
• Alix-Panabieres, C., Riethdorf, S., Pantel, K. (2008). Circulating Tumor Cells and Bone Marrow Micrometastasis. Clin. Cancer Res. 14: 5013-5021 [Abstract] [Full Text]  
• Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., Steeg, P. S. (2008). Effect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain. JNCI J Natl Cancer Inst 100: 1092-1103 [Abstract] [Full Text]  
• Nunes, C B, Rocha, R M, Reis-Filho, J S, Lambros, M B, Rocha, G F S, Sanches, F S F, Oliveira, F N, Gobbi, H (2008). Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol. 61: 934-938 [Abstract] [Full Text]  
• Peppercorn, J., Partridge, A. H. (2008). Breast Cancer in Young Women: A New Color or a Different Shade of Pink?. JCO 26: 3303-3305 [Full Text]  
• Rowe, D. L., Ozbay, T., Bender, L. M., Nahta, R. (2008). Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Molecular Cancer Therapeutics 7: 1900-1908 [Abstract] [Full Text]  
• Trotta, F., Apolone, G., Garattini, S., Tafuri, G. (2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol 19: 1347-1353 [Abstract] [Full Text]  
• Walker, R A, Bartlett, J M S, Dowsett, M, Ellis, I O, Hanby, A M, Jasani, B, Miller, K, Pinder, S E (2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61: 818-824 [Abstract] [Full Text]  
• Gomez, H. L., Doval, D. C., Chavez, M. A., Ang, P. C.-S., Aziz, Z., Nag, S., Ng, C., Franco, S. X., Chow, L. W.C., Arbushites, M. C., Casey, M. A., Berger, M. S., Stein, S. H., Sledge, G. W. (2008). Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer. JCO 26: 2999-3005 [Abstract] [Full Text]  
• Finn, O. J. (2008). Cancer Immunology. NEJM 358: 2704-2715 [Full Text]  
• Conrad, H., Gebhard, K., Kronig, H., Neudorfer, J., Busch, D. H., Peschel, C., Bernhard, H. (2008). CTLs Directed against HER2 Specifically Cross-React with HER3 and HER4. J. Immunol. 180: 8135-8145 [Abstract] [Full Text]  
• Mayer, M. (2008). Swimming Upstream: An Advocate Reflects on Cancer Research and Social Realities. JCO 26: 2783-2786 [Full Text]  
• MacKenzie, R., Chapman, S., Salkeld, G., Holding, S. (2008). Media influence on Herceptin subsidization in Australia: application of the rule of rescue?. JRSM 101: 305-312 [Abstract] [Full Text]  
• Kulkarni, S., Hicks, D. G. (2008). HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. Ann. Surg. Oncol. 15: 1677-1688 [Abstract] [Full Text]  
• Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J. I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. S., Srimuninnimit, V., Colleoni, M., Coates, A. S., Piccart-Gebhart, M. J., Goldhirsch, A., for the HERA Study Team, (2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19: 1090-1096 [Abstract] [Full Text]  
• Belkacemi, Y., Gligorov, J., Ozsahin, M., Marsiglia, H., De Lafontan, B., Laharie-Mineur, H., Aimard, L., Antoine, E.-C., Cutuli, B., Namer, M., Azria, D. (2008). Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19: 1110-1116 [Abstract] [Full Text]  
• Perez, E. A., Koehler, M., Byrne, J., Preston, A. J., Rappold, E., Ewer, M. S. (2008). Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials. Mayo Clin Proc. 83: 679-686 [Abstract] [Full Text]  
• Walker, R A (2008). Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol. 61: 689-696 [Abstract] [Full Text]  
• Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S. (2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist 13: 620-630 [Abstract] [Full Text]  
• Contessa, J. N., Bhojani, M. S., Freeze, H. H., Rehemtulla, A., Lawrence, T. S. (2008). Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells. Cancer Res. 68: 3803-3809 [Abstract] [Full Text]  
• Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., Zhang, Z., Reilly, R. T., Apostolidis, C., Morgenstern, A., Sgouros, G. (2008). 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model. Cancer Res. 68: 3873-3880 [Abstract] [Full Text]  
• DiGiovanna, M. P., Stern, D. F., Edgerton, S., Broadwater, G., Dressler, L. G., Budman, D. R., Henderson, I. C., Norton, L., Liu, E. T., Muss, H. B., Berry, D. A., Hayes, D. F., Thor, A. D. (2008). Influence of Activation State of ErbB-2 (HER-2) on Response to Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil for Stage II, Node-Positive Breast Cancer: Study 8541 From the Cancer and Leukemia Group B. JCO 26: 2364-2372 [Abstract] [Full Text]  
• Nguyen, P. L., Taghian, A. G., Katz, M. S., Niemierko, A., Abi Raad, R. F., Boon, W. L., Bellon, J. R., Wong, J. S., Smith, B. L., Harris, J. R. (2008). Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. JCO 26: 2373-2378 [Abstract] [Full Text]  
• Li, X., Lewis, M. T., Huang, J., Gutierrez, C., Osborne, C. K., Wu, M.-F., Hilsenbeck, S. G., Pavlick, A., Zhang, X., Chamness, G. C., Wong, H., Rosen, J., Chang, J. C. (2008). Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. JNCI J Natl Cancer Inst 100: 672-679 [Abstract] [Full Text]  
• Willis, A. L., Tran, N. L., Chatigny, J. M., Charlton, N., Vu, H., Brown, S. A.N., Black, M. A., McDonough, W. S., Fortin, S. P., Niska, J. R., Winkles, J. A., Cunliffe, H. E. (2008). The Fibroblast Growth Factor-Inducible 14 Receptor Is Highly Expressed in HER2-Positive Breast Tumors and Regulates Breast Cancer Cell Invasive Capacity. Mol Cancer Res 6: 725-734 [Abstract] [Full Text]  
• Muller, M., Obeyesekere, M., Mills, G. B., Ram, P. T. (2008). Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J. 22: 1393-1403 [Abstract] [Full Text]  
• Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., Mavroudis, D. (2008). Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. Clin. Cancer Res. 14: 2593-2600 [Abstract] [Full Text]  
• Portera, C. C., Walshe, J. M., Rosing, D. R., Denduluri, N., Berman, A. W., Vatas, U., Velarde, M., Chow, C. K., Steinberg, S. M., Nguyen, D., Yang, S. X., Swain, S. M. (2008). Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Clin. Cancer Res. 14: 2710-2716 [Abstract] [Full Text]  
• Montemurro, F., Redana, S., Valabrega, G., Martinello, R., Aglietta, M., Palmiero, R. (2008). Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. JCO 26: 2052-2053 [Full Text]  
• Sachdev, D., Yee, D. (2008). Disrupting Insulin-Like Growth Factor Signaling as a Potential Cancer Therapy. aacredbook 2008: 39-58 [Abstract] [Full Text]  
• Pantel, K., Alix-Panabieres, C., Riethdorf, S. (2008). Circulating Tumor Cells: Detection and Clinical Relevance. aacredbook 2008: 603-610 [Abstract] [Full Text]  
• Brandt, B. H (2008). Single/Oligo-Cell PCR: Needs, Perspectives, and Limitations. aacredbook 2008: 625-628 [Abstract] [Full Text]  
• Baker, J. H.E., Lindquist, K. E., Huxham, L. A., Kyle, A. H., Sy, J. T., Minchinton, A. I. (2008). Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts. Clin. Cancer Res. 14: 2171-2179 [Abstract] [Full Text]  
• Pant, S., Landon, M. B., Blumenfeld, M., Farrar, W., Shapiro, C. L. (2008). Treatment of Breast Cancer With Trastuzumab During Pregnancy. JCO 26: 1567-1569 [Full Text]